Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma

NCT07156019 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Carcinomas (NEC)

Interventions

DRUG: Sintilimab+Temozolomide+Surufatinib

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences